DocGo Inc. (DCGO) Earnings Call Transcript & Summary

May 8, 2025

NASDAQ US Health Care Health Care Providers and Services earnings

Earnings Call Speaker Segments

Mike Cole

executive
#1

Thanks, operator. Before we hand things over to management, I want to offer a few comments about forward-looking statements. Everything said on this conference call that isn't a statement of historical fact counts as a forward-looking statement. Terms such as will, plan, potential, could, goal, outlook, design, anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, project, and similar expressions might be used to flag those forward-looking statements. Such forward-looking statements don't guarantee future performance, and we can't assure you that our plans, intentions, outcomes, results, or expectations will be achieved or realized. Forward-looking statements carry inherent exposure to substantial risks, uncertainties, and assumptions, a great many of which lie beyond our control and could cause our actual results or outcomes, or when results or outcomes occur, to differ materially from what our forward-looking statements contain; among these risks, uncertainties, and assumptions are, without limitation, those addressed in our risk factors and elsewhere in DocGo Inc.'s annual report on Form 10-Ks, quarterly reports on Form 10-Q, our earnings release for this quarter, and other reports and statements DocGo Inc. has filed with the SEC, to which we direct your attention. Actual outcomes and results, or when results occur, may differ materially from what these forward-looking statements express or imply. Today's call also includes references to non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most directly comparable GAAP financial measures appear in our earnings release or the current report on Form 8-Ks that includes our earnings release, which is posted on our website, DocGo.com, and also filed with the SEC. What you hear on this call is accurate only as of the date discussed. Investors shouldn't assume statements will stay relevant and operative later on. We're under no obligation to update any information discussed on this call to reflect events or circumstances arising after the date of this call, or to reflect new information or the occurrence of unanticipated events, except to the extent the law requires. At this point, it's my pleasure to turn the call over to Mr. Lee Bienstock, CEO of DocGo Inc. Lee, please go ahead.

Lee Bienstock

executive
#2

Thanks, Mike, and thanks to everyone for being on the call today. I'd like to begin by talking about the significant choice we made to take our government population health vertical out of our 2025 guidance, and after that, lay out the growth plans we have for our hospital system medical transportation and payer provider verticals, both for this year and for next. First, on our government population health vertical. Continuous policy shifts and budget reductions in Washington have generated a great deal of uncertainty and hesitancy when it comes to new municipal project launches, and with the government RFP channel overall; as a matter of fact, we're experiencing major delays in municipal decision-making as well as delays to launch timelines for contracts we've already signed. Within our pipeline there are 35 open government RFP submissions, several of which went in more than six months ago and we still haven't heard back. On top of that, we have signed contracts in this vertical that were ready for launch, but whose implementation has been paused as a direct consequence of the uncertainty in this channel. So we can no longer count on these to bring in meaningful revenue during this calendar year. Consequently, we've chosen to move non-migrant government population health revenue and related projects out of our 2025 guidance. Along with that decision, we revised our 2025 guidance from $410 million to $450 million in revenue with a 5% adjusted EBITDA margin down to $300 million to $330 million, with an expected adjusted EBITDA loss of $20 million to $30 million. Let me be clear that this guidance revision is tied specifically to our government population health vertical. The remainder of our business keeps performing as we anticipated; and we believe it's on a strong growth trajectory; this year, we still expect roughly $225 million in revenue from our medical transportation services, $50 million from our payer and providers, and $50 million from our remaining migrant services health care work, all unchanged from what we previously expected. Any new municipal work would come in as incremental to our revised 2025 guidance, and if it's realized, we intend to break it out as upside revenue in future quarters. We're building our company around our innovative solutions for payers, providers, and health systems, and we have tremendous confidence in our mobile health at any address and medical transportation offerings. To me, these businesses represent both the foundation and the future of DocGo Inc. And I'm eager to share our key metrics and projected growth rates for this year and the next. Our medical transportation business keeps performing well and, on a contribution basis, is expected to deliver adjusted EBITDA of greater than $15 million in 2025. We saw record trip volume in the first quarter of 2025, and we expect that momentum to carry into the second half of this year, finishing 2025 at approximately 575,000 total transports. On top of that, we see ongoing revenue growth ahead, powered by a significant new client win in the Northeast, plus further expansion across Texas and the UK. And we think we can get close to 700,000 transports by the close of 2026. Health systems keep looking for partners capable of delivering high-quality, technology-enabled medical transportation solutions that give their patients timely, dependable service; we've put investment into a technology platform that connects with leading EHRs, Epic among them, and offers unmatched transparency to our customers and their patients. Feedback from our health system partners stays consistently positive, and we think our technology is a crucial point of differentiation and that it allows us to land new contracts. Within our payer and provider vertical, we keep seeing considerable growth, and I'm happy to report that we've now passed 900,000 assigned lives since our Care Gap closure program began, rising from 700,000 only a quarter earlier. Along with growth in assigned lives, I wanted to show how our visit volume has increased over time. During the fourth quarter of 2023, we finished roughly 2,500 care gap closure and transitional care management visits. By the fourth quarter of 2024, our count of gap closure and TCM visits had climbed to more than 4,400. For the fourth quarter of 2025, we project finishing more than 11,500 care gap closure and TCM visits. Said differently, this business is set to quadruple across a 24-month span; we're collaborating with our payer customers to keep broadening our capabilities with Evergreen Services such as pediatric care gap programs. Those have experienced a major rise in volumes, with more than 2,500 visits finished so far this year; such services cover well visits, vaccinations, and fluoride treatments, for underserved children. Furthermore, we recently signed our first substantial PCP agreement with a major payer in the Northeast, which marks a very significant step forward; in our long-term strategic vision. For context, during 2024, we completed 44 PCP visits. That figure should climb to 10,000 this year and beyond 40,000 in 2026. Also, in Q1, we brought PTI Health, a mobile lab collection and phlebotomy company, into our portfolio. They're on pace to finish more than 125,000 blood draws in patient homes during 2025, and we expect them to surpass 200,000 in 2026. Altogether, across our Caregap program, PCP and mobile lab businesses, we expect to visit more than 150,000 patients in their homes this year; we remain convinced that our capacity to bring care into the home economically and efficiently at scale leaves us in a uniquely valuable strategic position. Not only can we work to positively impact patient outcomes and drive savings for our payer customers, but we can also gain a significant data advantage in the home regarding the variables that directly impact a patient's health. We can genuinely guide a patient all the way across that spectrum. Starting from someone not involved at all, with minimal information, and chronic illnesses that nobody is treating, and bringing them to a state of active participation with full at-home data, all while helping make preventive care happen. The financial gains here are significant, and we're setting up this company to steadily claim an ever-growing share of those gains going forward. Beyond the money saved and better results, our patients truly adore what we provide. During Q1, the mobile health net promoter score at DocGo Inc. came in at 86. That's far above the average NPS for the healthcare sector, which sits at 58. Moving to EBITDA, the main reason we expect an adjusted EBITDA loss for 2025 comes from our SG&A being too high relative to revenue throughout this transitional stretch. That's because we're phasing out the migrant-related side of the business at the same time we're putting money into backing our expanding medical transportation arm, plus the payer and provider mobile health verticals, along with our technological edge. Even as we commit these funds, which we feel will produce a meaningful return across our three-year growth plan, we've already begun taking steps to trim costs. During the first quarter of 2025, we brought SG&A down by roughly $3.1 million sequentially, and we intend to cut SG&A aggressively across the coming quarters too. We're confident these actions will get us to positive adjusted EBITDA in 2026. Now, on the topic of our balance sheet. It's still in good shape. Even though we're forecasting a consolidated adjusted EBITDA loss for the year, we still expect operations to generate positive cash flow and anticipate finishing the year holding more than $110 million in cash, once we factor in $9 million of stock repurchases made so far this year, $4 million for buying PTI, and paying back $30 million against our revolving line of credit, which leaves us able to end the year with no debt. We keep building a company that delivers a distinctive value proposition to payers, providers, and health systems. And our expansion in 2025 and afterward will stem from the performance of our established medical transportation business and our growing mobile health payer and provider operations; should we activate any meaningful non-migrant municipal work during this year, revenue from those projects will be reported separately in later quarters and will act as upside to our 2025 guidance. To wrap up, for 2025, we anticipate our medical transportation business bringing in $225 million in revenue, our payer and provider business bringing in $50 million, and $50 million from the remaining migrant services health care work. We're pursuing cost-cutting and cost containment efforts on our SG&A base, and we have a solid balance sheet to finance and support our ongoing business growth. I have strong confidence in the proven value of our company and what we offer. And I'm eager about what we have planned ahead. Now I'll pass things to Norman Rosenberg to go over the financials; during 2024, we completed 144 PCP visits.

Norman Rosenberg

executive
#3

Thanks, Lee. Good afternoon, everyone. For Q1 2025, total revenue came in at $96 million, versus $192.1 million during the same period in 2024. That drop in revenue stemmed completely from the government vertical, mostly from projects tied to migrants. As we've noted across the last several quarters, our migrant-related work hit its peak during Q4 2023 and Q1 2024, then started winding down in May 2024 when we exited the sites based in New York City. By the close of 2024, we had exited every HPD site, and the migrant work that remains with New York City Health and Hospitals should be largely finished by the middle of this year. Mobile health revenue in Q1 2025 reached $45.2 million, a decrease from $143.9 million in Q1 of last year, which was driven by this expected wind down of migrant revenues. Medical transportation services revenue rose to $50.8 million in Q1 of 2025, up from $48.2 million in transport revenues recorded during Q1 of 2024. Those revenues got a lift from gains in a number of markets, such as Delaware, Tennessee, Pennsylvania, New Jersey, Wisconsin, Upstate New York, and The UK. Looking at the first quarter, mobile health brought in about 47% of our total revenues, and medical transportation accounted for 53%. For Q1 2025, we recorded a net loss of $11.1 million, compared to net income of $10.6 million in Q1 of 2024 — that swing reflects the revenue drop I just described. Adjusted EBITDA in Q1 2025 was a loss of $3.9 million, against adjusted EBITDA of $24.1 million in Q1 of 2024. Our total GAAP gross margin percentage for Q1 2025 was 28.2%, versus 32.8% in Q1 of 2024. When we exclude depreciation and amortization, adjusted gross margin came in at 32.1% for Q1 of 2025, compared with 35% in Q1 of 2024. For the mobile health segment in the first quarter of 2025, adjusted gross margin came in at 30.8%. That compares to 35.5% during the same quarter in 2024. The early stage payer and provider business drove most of that difference. Because that business grew while migrant revenues declined, payer and provider had a larger effect on mobile health gross margins overall. Still, with continued growth in that business, we expect our clinicians — who make up the bulk of cost of goods sold — to see improved utilization rates. We believe that improved utilization will lead to stronger gross margins for this business line and, over time, will raise the entire mobile health segment. Looking at medical transportation, adjusted gross margin came in at 33.3% for Q1 2025, compared with 33.7% during the same quarter a year earlier. Although that segment's margins improved by more than 300 basis points quarter over quarter relative to the first fourth quarter of 2024, Q1 still saw pressure from elevated personnel-related expenses in one of our bigger markets. Going forward through 2025, we anticipate medical transportation gross margins will keep improving on a sequential basis. Now on to operating costs. SG&A represented 46.7% of total revenues in the first quarter of 2025, up against 26.8% in the first quarter of 2024. With migrant revenue declining across the last few quarters, SG&A has risen noticeably as a share of overall revenues. Still, looking at actual dollars, those expenses fell 13% compared with a year earlier in Q1 2025, and they declined 7% versus the Q4 2024 figure on a sequential basis. Cost reductions are underway within the business, and throughout 2025 we'll keep concentrating on bringing SG&A costs down. That said, for the coming quarters or so, we anticipate SG&A expense will stay high relative to revenues if you measure it against the levels we saw previously. Even with the net loss and adjusted EBITDA in negative territory, Q1 brought in $9.7 million of positive operating cash flow, driven by ongoing collection of our older, larger invoices. That said, we ended Q1 with less cash than we had at the close of 2024, because of outlays for our stock buyback program and the PTI Health acquisition. On March 31, 2025, total cash and cash equivalents, restricted cash included, stood at $103.1 million — a slight dip from $107.3 million at the end of 2024, though roughly $44 million higher than the same point a year earlier. Our accounts receivable kept shrinking. This mirrors the money we've been bringing in and how income tied to migrant programs has been tapering off since the midpoint of Q2 2024. When the quarter closed, receivables connected to those migrant programs totaled roughly $120 million, amounting to around two-thirds of all consolidated AR across the company. That's down from $150 million in migrant-program AR at the close of 2024, when it made up about 71% of the company's overall total. Even though revenue took a hit from the phasing out of programs tied to migrants, we anticipate a sizable boost to our balance sheet during 2025 as that accounts receivable gets collected. That will drive better cash flow from operations, and it ought to be sufficient to offset whatever operating losses arise. We still anticipate being positive on operating cash flow for the year, even with adjusted EBITDA projected to be negative in 2025. All of this stems from those favorable shifts in our working capital. There are times when the speed at which New York City sends payments frustrates us, but those payments do arrive on a consistent basis, and we anticipate that continuing to collect these receivables will help drive an increase in our total cash balances; our view is that this will give us the means necessary to put money into our growth and to strengthen our balance sheet. Executing our stock buyback program was one method we used to deploy cash in the first quarter. Nearly 2 million shares were bought back by us through open market purchases across the quarter, at a total cost of roughly $5.8 million. Thus far in Q2, following the provisions of our 10b5 to 1 trading plan, an additional 1.2 million shares have been repurchased by us for a further $3.2 million. With almost $9 million spent on our repurchases to date this year, a further $13 million is still available to us under this program. Our cash balance was also used in the quarter to expand our capabilities, through the acquisition of PTI Health, a company focused on mobile lab collection and phlebotomy. Additional acquisitions are being weighed by us across the remainder of 2025, since we aim to keep leveraging our resources to extend our reach and clinical service offerings. Having said that, I'd now like to turn things over to the operator so we can move into the question-and-answer portion. Operator, the floor is yours.

Ryan MacDonald

analyst
#4

Hello, and thank you for allowing me to ask my questions. I'm sorry to learn about the lack of clarity in the government vertical, but perhaps we can begin right there. When you consider the rest of the year quarter by quarter, could you provide some indication of roughly what government revenue you anticipate in each quarter and how we should think about the mix of where that revenue gets removed? After that, how are you approaching the strategic task of balancing SG&A reductions to improve the P&L against ensuring your staff is prepared to launch these government engagements should they begin later in 2025 or in 2026?

Lee Bienstock

executive
#5

Of course. Thank you, Ryan. I appreciate that question. Regarding the government population health vertical, we chose to take those revenues out of our 2025 guidance; therefore, any significant population health revenues generated by the non-migrant population health programs will be reported separately as upside on top of the 2025 guidance we revised earlier today. Consequently, any substantial new deployments in the government population health vertical will be described, explained, and reported separately going forward — this quarter and in subsequent quarters for the rest of the year. That said, we are experiencing considerable delays in timelines. We won multiple different contracts that were supposed to launch but have not launched as of yet. We turned in several RFPs from which we ought to have received responses, yet we are still awaiting those responses. So when those RFPs reach completion, when those projects we have already signed begin, we will report on them during upcoming quarters. And that will come on top of the revised 2025 guidance we updated today. As for the SG&A base, you described it precisely. We are balancing restructuring with reinvesting across various parts of our business; thus, as Norm said, we are definitely examining all of our shared services departments in search of savings. Within those departments, we are also directing resources back into the growing areas of the company on the payer and provider side as well as the medical transportation side. So we do expect additional growth through the rest of this year and into the next, and we want to be certain we are positioned and prepared for that growth. We have many excellent team members who are helping scale the business, and so we will redeploy those team members into the growing areas of the business and the new areas of focus for the company. Beyond that, yes, we are conducting a thorough review of restructuring several of the various shared services departments to find savings we can remove from SG&A there.

Norman Rosenberg

executive
#6

Ryan, this is Norm. You'd asked about what taking those government revenues out of our guidance does. Roughly speaking, call it around $100 million. As you remember, we said before that we'd anticipated Q2 might be the revenue trough for the company, back when we assumed all of that government revenue would be included, and Q2 clearly is when the complete wind down would happen. Regarding the migrant program — but then much of what Lee is referencing, either things with a signed contract that hasn't launched, or items we're still waiting to learn about, would have begun contributing in Q3 and Q4. So looking at it today, I'd say Q2 revenue, as we always anticipated, will clearly come in below what you saw in Q1. Q3 will likely fall even more, since no migrant revenue — no material migrant revenue — will be there in that stretch, and none of this government revenue is assumed to arrive. Then we likely see a small blip upward from Q4 versus Q3, though Q4 stays under Q2's levels. That's roughly how the quarterly path shifts given the guidance changes we've made.

Ryan MacDonald

analyst
#7

Thanks for all those details. Moving on to something more positive — the payer side of the business keeps expanding very quickly, and it looks like you're finding a great deal of success there. Could you discuss the demand you're observing in the end market for the payer segment? And clearly, we've picked up quite a bit of commentary from UnitedHealth about a large number of lives shifting, moving unmanaged MA lives into different plans. I'm curious whether that's driving some additional demand for the Caregap closure offering; and then are there any initial indicators of traction from the AB testing you've been running aimed at boosting patient engagement in that care gap closure program? Thanks.

Lee Bienstock

executive
#8

For sure. So, as you said, Ryan, demand looks strong in Caregap closure, PCP, essentially, at any address, healthcare in the home business. That's for the precise reasons you brought up. To start, the plans we partner with are looking to solve for either one or both or two main goals. First, they definitely want to bring down their medical loss ratio; they're aiming to cut their healthcare spending; and so the preventative proactive screenings we perform in the home, the proactive healthcare we deliver in the home, is squarely aimed at lowering ED readmissions, hospitalizations, and we're finding extremely strong results — our cohorts of patients are going back to the hospital at significantly reduced rates. So that's definitely something health plans care about. They don't want members in the hospital; that's the most costly setting. And as you pointed out, medical expenses are clearly climbing. MLR is a major priority for these plans. So we're assisting them with that. The second element is we also support plans with their quality metrics. So the more care gaps we can close in the home, the better, since their quality metrics and their HEDIS measures will rise; and you brought up additional MA members entering the market; that will certainly assist them with enrollments, that will help them with plan choice and people selecting those MA plans. So the higher quality they are, obviously, the more appealing they are to MA members; so we're assisting in both those scenarios. We average for every visit we do in the home. Right now we're averaging roughly two care gaps closed. So for every visit, we're averaging more than one care gap. And in certain cases, we've even closed six care gaps in one visit. You can picture how accretive that is for the health plans and obviously as some of these managed plans and as the managed market overall grows, we expect over the coming years here, we're going to have an increasingly larger role to play.

Ryan MacDonald

analyst
#9

Great, that's good to hear. I appreciate the additional detail. I'll rejoin the queue.

Lee Bienstock

executive
#10

Thank you, Ryan.

Kieran Ryan

analyst
#11

Hello there. Kieran Ryan here, filling in for Pito Chickering. I appreciate you taking my questions. I just wanted to see whether we could get a bit more detail about what exactly took place between February, when you last reported, and the close of this quarter. Because even when I look at the 1Q results, it appears there's a fairly sizable miss. So I'd just like to know if anything was canceled during March, or if you could simply discuss the quarter and explain how that feeds into the guidance decision. Thank you.

Lee Bienstock

executive
#12

Of course, Kieran. Of course. During our prepared remarks, we explained that this adjustment stems straight from the decision we reached about the government population health vertical, plus how we'll forecast and disclose those revenues moving forward. Medical transportation and our payer provider business — both stay completely on schedule. Nothing has changed in what we expect from them. The specific thing that moved regarding the government population vertical is that a great deal of wavering and delay has emerged, spanning everything from the federal government all the way down to local municipalities. And given these policy shifts originating in Washington — as I mentioned, contracts we've already signed are sitting stalled. We're waiting on the RFP channel. So, until we get more clarity, we made a decision — you brought this up between the previous call and this one — to take those out of the revenue guidance, and they'll act as a kind of upside, and we'll report on them separately. So that's the change. As Norm mentioned, when you pull out roughly $100 million from the revenue guidance, that's just how the business model swings — a positive EBITDA expectation of 5%. You know, it shifts to the $20 to $30 million adjusted EBITDA loss. When you remove that revenue. If that vertical turns around and starts bringing in substantial revenue, that would be extra upside, and we'd report it separately. Meanwhile, like I mentioned, things are going really well in the payer and provider vertical. I think that's showing up in these results, and the same goes for our medical transportation vertical, where we're working hard to meet the demand. We want to give everyone a transparent view of how those verticals are performing at a fundamental level. On today's call, we provided many more metrics covering those verticals, and we'll keep doing so on future calls. To put it briefly, the main difference between the prior call and this one is that we deliberately made a strategic choice to take those municipal revenues out of the guidance and instead treat them as upside that will be reported in future quarters.

Norman Rosenberg

executive
#13

Sure. And Kieran, regarding the effect on Q1 relative to what was expected: yes, even against our own internal figures, I'd say we were probably at the top line. We were rounding it; our expectation was roughly $100 million. We landed at $96 million. Now, breaking it down, transport actually performed slightly better than we'd anticipated. In most of our markets, results were, you know, a couple hundred grand above what we'd perhaps assumed, and overall a few hundred thousand higher. Migrant revenue by itself, roughly $36 million for the quarter, came in somewhat soft versus what we'd laid out, since dates shifted on us somewhat. You'd lose a couple days here and there. Plus the wind down was occurring along a somewhat different path. When you're handling that bigger figure, clearly even a slight variation in shift counts or headcount is going to cause movement; but that portion of the business is disappearing regardless. And then in mobile health, the segment of our business supplying staffing for general government programs was likewise somewhat lower. I won't claim that's due to the general uncertainty we've been discussing. That was likely just a question of performance in how things played out during the quarter; but that, you know, the shortfall, so to speak, on the top line versus the expectation was fully attributable to the government vertical.

Kieran Ryan

analyst
#14

Got it, that helps for the quarter, thank you. Then a quick follow-up. On the other payer and provider verticals, I'm grateful for the extra detail. I was just hoping to understand how you see that scaling on the revenue and EBITDA lines for those two. I think you said it was $50 million of revenue on that. So I'm just trying to figure out whether you're still actively onboarding new projects there. And with everything else shifting, it's just hard to tell — so thanks for taking the questions.

Lee Bienstock

executive
#15

Sure. We are absolutely adding new programs there, and we actually expect it to speed up. As we look toward the latter portion of the year, our plans are focused on closing out strong, addressing the needs of patients with unresolved care gaps, and we're seeing a great deal of momentum building for that period. New customers continue to join us in that area. Our pipeline remains quite robust. With each passing quarter, we expect to deliver a growing number of both care gap visits and PCP visits as the year progresses and, naturally, on into the following year. So that's certainly happening there. On the subject of margins, this is fundamentally a business in its early stages, and we're currently in a scaling-up phase. Looking ahead to next year, we expect gross margin for that business to approach 40%. Right now, our margins remain below where we want them, since we're still scaling up and building density in the markets where we're most focused. That said, we couldn't be more excited about how this business is growing. Patients clearly love it, and the plans love it too. As was mentioned earlier, as plans work toward closing out the year, they need to reach patients with open gaps in care — people who haven't visited their doctor. We can step in and serve those patients, seeing them at home and offering a care modality that may not have been accessible to them before. Adoption has been absolutely massive for us. Beyond that, we're putting substantial resources behind our efforts on patient conversion and engagement. Whenever payers hand us rosters of patients with unaddressed care gaps, we're creating a best-in-class system for reaching out to those individuals, arranging their appointments, assigning clinicians, mapping their routes, and organizing the schedule so each clinician enjoys a fully booked, productive, high-quality day out in the field. The more we scale this up, the better our margins will get from that point forward, so we're genuinely excited about what we're developing in this area. And as I said earlier, patients are loving it. We're going to keep putting a great deal of our resources back into that business. That figure of $50 million you brought up — it hasn't moved. It's the number we've been using. It's what we're aiming for. We'll hit it on the timeline we set. Nothing has changed on that goal for payers and providers; if anything, I'd tell you we're moving faster than we had anticipated.

Norman Rosenberg

executive
#16

Okay, so Kieran, you need to think forward here, because right now, like Lee mentioned, that segment is pulling down our total consolidated margin. My estimate is that it likely shaved somewhere between 1 and 1.5 points off the consolidated adjusted gross margin figure we posted, which was 32.1. Yet in the end, that segment will turn into the highest-margin part of our business. Within that specific vertical, we have lines of business that will achieve gross margins above 50%. So, as you know, that will clearly lift the consolidated figure over time. When it comes to leading indicators, looking at KPIs and forward signals matters a lot to us since our focus is on what's ahead; therefore, the main thing driving that is clearly how much the clinicians are utilized. Correct? The more visits they can handle, or the more trips they can complete, or the number of patients they can see within an hour or across a ten-hour shift or an eight-hour shift, you know, the margin rises accordingly; and I'd add that what we're seeing early on is promising. So, the utilization rate so far, you know, the first—what is it—5 weeks of Q2, is roughly 30% above where it stood in Q1. They're trending. Should this trend hold, they're tracking at a level we hadn't actually forecast until some point in 2026 or 2027. So if we're able to sustain those sorts of figures as we grow, then I believe you could even witness a sharper climb toward that strong and healthy gross margin. However, right now, looking at Q1, it definitely weighed on the overall gross margin for the business.

Kieran Ryan

analyst
#17

Many thanks. I appreciate that.

Gabby

analyst
#18

Hello, everybody. Gabby here, filling in for Sarah. One quick thing I wanted to ask about — the government sector comes to roughly $100 million, yet it seems like the guidance got reduced to $115 million. Could you walk through what accounts for the difference between those two figures, or is that simply baked-in conservatism within the guidance?

Norman Rosenberg

executive
#19

Yep. Yeah. What you said in the latter portion there is right. As a matter of fact, Lee mentioned a few times during his remarks earlier that we're holding at $225 million for transport. We remain at $50 million for migrant, and $50 million for those care gap closures and payer programs. That, you know, clearly comes to $325 million in total. Whereas our guidance range stood at $300 million to $320 million, which lands you at $315 million. So that's essentially the situation; we're merely aiming to be prudent and factor in something for the spectrum of outcomes across every one of our business lines.

Gabby

analyst
#20

All right. That's great. So, when you say 2026 ought to be EBITDA positive, does that mean EBITDA positive with zero input from the government vertical? And then, real quick on the payer and provider side, with those positive 2026 MA rates, are conversations turning more favorable? And perhaps payers now have greater room to bring in some of your offerings.

Lee Bienstock

executive
#21

Yes; so, like we said, the municipal population health vertical, right, that would come on top moving forward. And it would also be on top in 2026 too. Reporting on that alongside the revenue guidance we're providing today and later on is what we intend to do. So that would sit on top of our EBITDA projections for next year. As for the payer and what's happening with MA, we definitely see that as a tailwind. That's what we're observing. I believe we've had a great many opportunities sitting in our pipeline dating back to last year, and the pipeline, even just across the last two weeks, is genuinely accelerating, which is what we anticipated heading into the sort of back half Q3 and Q4 of this year. But we're witnessing enormous appetite for those services. So one piece of it comes from the macro element of what's taking place in the MA market. Yet another piece is simply that we keep accumulating more and more data, and our pitch keeps getting stronger and stronger, since we can demonstrate the ROI. We can demonstrate the patient happiness. We can demonstrate the impact we're delivering. We can demonstrate how many patients we've even managed to close care gaps with. They report back to their plans that they're pleased with the service. Clearly, patient satisfaction, member satisfaction counts as a major piece of the quality score for the MA plans. So all of that is likewise assisting us as we scale. Not only do we sharpen our operations, but as we scale, we simply have more and more data, more and more experience, more and more references for other plans. Plans pass us along from one state to the next and refer us. And so all of that, as we perform well, and we're investing. We want to ensure that these plans love us. We want to ensure, because there's simply so much opportunity, that the patients love us and that we're genuinely improving their health outcomes. And once we can do all of that, you know, there's enormous opportunity ahead of us.

Gabby

analyst
#22

All right. Great. Thanks, everyone.

Jenny Shen

analyst
#23

Hello. Jenny Shen here, filling in for David Larsen. I’m sorry if this was already covered or if you brought it up, but could you remind us what margin profile the migrant-related revenue has compared with your core business? And then, just to be clear on tariffs, I know we’ve discussed the anticipated effect on your fleet and what it costs to manage your fleet. But is there any potential tariff risk to some of the medical equipment you use and the wearable devices in the home? Thank you.

Norman Rosenberg

executive
#24

Okay. I’ll begin with what you asked about the margin profile for the migrant program. That program’s margins came in at roughly 34%, and it’s fairly steady, in fact. It was 34% during Q4, and 34% once more. Plus or minus a few basis points in Q1. So viewed that way, in the fourth quarter, mobile health gross margin was 35.9%. So, strictly speaking, the remaining portion — you know, the non-migrant part of mobile health — was running at a stronger margin. In this case, it worked the opposite way. So because the mix shifted away from migrant and toward other areas like the payer and provider programs, that clearly pushed margins lower, meaning the mix caused the decline. But I’d say approximately 34% or thereabouts is what we’re observing from the migrant work. Would you like to handle the tariff question?

Lee Bienstock

executive
#25

When it comes to tariffs, Jenny, it's just like you said — I believe they'd apply to our fleet. Clearly, we operate a large fleet, close to a thousand vehicles. And the way tariffs would enter the picture, I think, is that we use a calculation to determine when we buy new vehicles rather than keep up the ones we already have. So we'd weigh the trade-off between, say, the increasing expense of buying a vehicle and the future cost of simply servicing the vehicles already in our possession, and we're positioned well to strike that balance; overall, our fleet is fairly new; beyond that, we have a fantastic, committed fleet management group that keeps our vehicles running. And as soon as maintaining a vehicle costs too much, that's the point at which we purchase a replacement; so tariffs could affect that calculation, but I have full confidence that our team does a fantastic job keeping the vehicles we have in service. We had already submitted orders for the new fleet we intended to buy for this year, and those have been ordered, priced, and paid for. So I'd say we're sitting in a good spot. That said, it obviously could push up prices for certain parts. You know, clearly, we traveled 8.8 million miles in the prior year, so that covers oil changes, tires, brake pads, and anything else you can think of that keeps such a huge fleet operating. But in the end, we'll evaluate the expense of maintaining versus the expense of purchasing new ones; yet as I mentioned, we planned ahead and we enjoy great scale. So this year, most of the orders we're aiming to place for procurement had already been submitted.

Norman Rosenberg

executive
#26

Right. Conversely, fuel expenses might decrease. What I mean is, at present they're already operating slightly under our earlier forecast. Plus, they're somewhat under where they stood 12 months back. So my view is the largest effect will be the one everyone encounters, namely the overall inflationary climate. Yet, once more, even inside an inflationary climate, crude prices are likely cheaper. Consequently, gasoline prices will be cheaper too. As you know, we hold some leverage regarding that, so it would amount to a net gain for us.

Jenny Shen

analyst
#27

Great, thanks.

Lee Bienstock

executive
#28

Thanks, and thanks to everyone for being with us here today. Take care.

Operator

operator
#29

That brings an end to the conference call for today. We appreciate all of you joining us. You're free to hang up at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.